Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran.
The Excellent Center for Dengue and Community Public Helath (EC for DACH), School of Public Health, Walailak University, Nakhon Si Thammarat, Thailand.
Infect Disord Drug Targets. 2022;22(2):e230921196758. doi: 10.2174/1871526521666210923144837.
Many potential vaccines for COVID-19 are being studied and developed. Several studies have reported on the safety and efficacy of these vaccines. This systematic review aimed to report on the current evidence concerning the feasibility and effectiveness of vaccines for COVID-19.
A systematic search was carried out utilizing the keywords in the online databases, including Scopus, Web of Science, PubMed, Embase, and Cochrane. We included both human and non-human studies because of the vaccine novelty, limiting our ability to include sufficient human studies.
This review showed several SARS-CoV-2 vaccines to be currently under development using different platforms, including eight vaccines that are adenovirus-based vectors, six vaccines that are RNA-based formulations, one vaccine being DNA-based formulation, and other vaccines using other platforms, including lipid nanoparticles. Although the safety and efficacy profiles of these vaccines are still under debate, some countries have allowed for emergency use of some vaccines in at-risk populations, such as healthcare workers and the elderly.
It is crucial to gather as much clinically relevant evidence as possible regarding the immunogenicity, efficacy, and safety profiles of available vaccines and adhere wisely to CDC protocols and guidelines for vaccine production.
目前正在研究和开发许多针对 COVID-19 的潜在疫苗。有几项研究报告了这些疫苗的安全性和有效性。本系统评价旨在报告关于 COVID-19 疫苗可行性和有效性的现有证据。
利用在线数据库中的关键词，包括 Scopus、Web of Science、PubMed、Embase 和 Cochrane，进行了系统搜索。由于疫苗的新颖性，我们包括了人类和非人类的研究，这限制了我们纳入足够的人类研究的能力。
本综述显示，目前正在使用不同平台开发几种 SARS-CoV-2 疫苗，包括八种基于腺病毒的疫苗、六种基于 RNA 的制剂、一种基于 DNA 的制剂以及其他使用其他平台的疫苗，包括脂质纳米粒。尽管这些疫苗的安全性和有效性仍存在争议，但一些国家已经允许在高危人群（如医护人员和老年人）中紧急使用一些疫苗。
收集关于现有疫苗的免疫原性、疗效和安全性的尽可能多的临床相关证据至关重要，并明智地遵守疾病预防控制中心关于疫苗生产的协议和指南。
